High yields and capping efficiencies

Cost-effective alternative for the industry standard

Read about it the Journal of American Chemical Society

J. Am. Chem. Soc. 2024, 146, 12, 8149–8163

Broad promoter compatibility

AvantCap® is compatible with plasmid templates containing T7 polymerase φ6.5 promoter both starting with AGG and GGG.

AvantCap® produces less dsRNA during in vitro transcription

AvantCap® is compatible with unmodified and modified uridines in vivo: hEPO in C57BL/6 mice

mRNA: human EPO | non-modified U or N1-MeΨ | Dose: 1 µg | Caps: Cap 1, AvantCap® | LNPs: LNP 2 (clinical grade) | Administration: intravenous

AvantCap® increases hEPO production up to 2-fold for N1-MeΨ mRNA and up to 6-fold when using natural UTP.